Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 5,130,000 shares, an increase of 12.3% from the June 15th total of 4,570,000 shares. Based on an average daily volume of 2,290,000 shares, […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) saw a large growth in short interest in June. As of June 30th, there was short interest totalling 5,130,000 shares, a growth of 12.3% from the June 15th total of 4,570,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is currently […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 5,130,000 shares, a growth of 12.3% from the June 15th total of 4,570,000 shares. Based on an average daily volume of 2,290,000 shares, […]
BioXcel Therapeutics (NASDAQ:BTAI – Free Report) had its target price decreased by HC Wainwright from $66.00 to $60.00 in a research note released on Monday morning, FlyOnTheWall reports. A number of other equities analysts also recently issued reports on the stock. Mizuho increased their price target on shares of BioXcel Therapeutics from $38.00 to $40.00 […]